Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Garau

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Journal of Medical Economics|July 2, 2014
Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH studyHelmut Ostermann, Francesco Blasi, Jesús Medina, et al.
International Journal of Antimicrobial Agents|September 26, 2002
The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adultsPatrick Petitpretz, Christian Chidiac, Francisco Soriano, et al.
Respiratory Research|January 24, 2014
Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH studyFrancesco Blasi, Helmut Ostermann, Jill Racketa, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 7, 2010
[Relationships with microbiology: the view from other specialties]Emilio Bouza Santiago, Javier Garau, Rafael Zaragoza Crespo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 6, 2004
[Hospital admission, duration of stay and mortality in community-acquired pneumonia in an acute care hospital. Correlation between a pneumonia prognosis index and conventional clinical criteria for assessing severity]Esther Calbo, Anna Ochoa de Echagüen, Mónica Rodríguez-Carballeira, et al.
International Journal of Antimicrobial Agents|February 9, 2011
Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?Ian M Gould, Roberto Cauda, Silvano Esposito, et al.
The Journal of Bone and Joint Surgery. American Volume|January 5, 2006
Foreign-body osteoarticular infection by Brucella melitensis: A report of three casesMireia Cairó, Esther Calbo, Lucía Gómez, et al.
The Journal of Infectious Diseases|June 3, 2006
Similarity between human and chicken Escherichia coli isolates in relation to ciprofloxacin resistance statusJames R Johnson, Michael A Kuskowski, Megan Menard, et al.
International Journal of Antimicrobial Agents|January 25, 2005
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strainsThomas M File, Javier Garau, Michael R Jacobs, et al.
Frontiers in Medicine|May 17, 2021
Related Factors to Streptococcus pneumoniae Invasive Infection and Clinical Manifestations: The Potential Role of Nasopharyngeal MicrobiomeBeatriz Dietl, Desirée Henares, Lucía Boix-Palop, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Journal of Medical Economics|July 2, 2014
Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH studyHelmut Ostermann, Francesco Blasi, Jesús Medina, et al.
International Journal of Antimicrobial Agents|September 26, 2002
The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adultsPatrick Petitpretz, Christian Chidiac, Francisco Soriano, et al.
Respiratory Research|January 24, 2014
Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH studyFrancesco Blasi, Helmut Ostermann, Jill Racketa, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 7, 2010
[Relationships with microbiology: the view from other specialties]Emilio Bouza Santiago, Javier Garau, Rafael Zaragoza Crespo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 6, 2004
[Hospital admission, duration of stay and mortality in community-acquired pneumonia in an acute care hospital. Correlation between a pneumonia prognosis index and conventional clinical criteria for assessing severity]Esther Calbo, Anna Ochoa de Echagüen, Mónica Rodríguez-Carballeira, et al.
International Journal of Antimicrobial Agents|February 9, 2011
Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?Ian M Gould, Roberto Cauda, Silvano Esposito, et al.
The Journal of Bone and Joint Surgery. American Volume|January 5, 2006
Foreign-body osteoarticular infection by Brucella melitensis: A report of three casesMireia Cairó, Esther Calbo, Lucía Gómez, et al.
The Journal of Infectious Diseases|June 3, 2006
Similarity between human and chicken Escherichia coli isolates in relation to ciprofloxacin resistance statusJames R Johnson, Michael A Kuskowski, Megan Menard, et al.
International Journal of Antimicrobial Agents|January 25, 2005
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strainsThomas M File, Javier Garau, Michael R Jacobs, et al.
Frontiers in Medicine|May 17, 2021
Related Factors to Streptococcus pneumoniae Invasive Infection and Clinical Manifestations: The Potential Role of Nasopharyngeal MicrobiomeBeatriz Dietl, Desirée Henares, Lucía Boix-Palop, et al.
Pageof 9